Dr Alan Trounson, president of the Californian Institute for Regenerative Medicine (CIRM), the largest agency funding human pluripotent and other stem cell research in the world, has recently visited Qatar Biomedical Research Institute (QBRI) to explore collaborative opportunities with the institute’s new Centre for Stem Cell and Regenerative Medicine.
He also gave a presentation entitled Stem Cells: A revolution in cell biology and regenerative medicine, as part of the Keynote
Lecture series.
“We are deeply honoured to have one of leading experts on stem cell research engage in QBRI’s knowledge transfer activities, both to the public of Qatar through the Keynote Lecture series, and to the QBRI team in meetings this week,” QBRI acting executive director Dr Abdelali Haoudi said.
He acknowledged that Dr Trounson’s insight, both as a researcher who led a team that discovered human embryonic stem cells and directed their differentiation into nerve and other tissue cells in the mid-1990s, and as the director of the one of the leading funding agencies of stem cell research, was of great value to QBRI and Qatar.
Dr Trounson also met with the QBRI scientists and management to discuss possible collaborations.
“QBRI is well-positioned to conduct high-impact research in the area of stem cells and regenerative medicine,” he said, adding: “I believe CIRM can engage with QBRI to develop collaborative research projects that will advance understanding of stem cells.”
Echoing similar view, Dr Haoudi said: “CIRM is at the centre of many stem cell research programmes, not only in California but around the world. The opportunity to collaborate with CIRM and CIRM-funded programmes would enhance QBRI’s Centre for Stem Cell and Regenerative Medicine.”
In his lecture, Dr Trounson described how CIRM has used part of its $3bn of voter-authorised funding to establish 12 new stem cell institutes.
The research supported by CIRM has resulted in more than 1,200 scientific publications (27% in high-impact factor journals).
CIRM has also enabled the formation of private-public research teams, focused on translational medicine, to prepare the way for clinical trials for a wide variety of diseases and injuries.
These include macular degeneration (loss of central vision); type I diabetes; targeting cancer stem cells in gliobastoma, leukaemias and solid tumours; HIV/Aids; stroke; and genetic diseases such as sickle cell disease, thalassemia.
Dr Alan Trounson: president, Californian Institute for Regenerative Medicine.